Methamphetamine-dependence Clinical Trial
Official title:
Repetitive dTMS Intervention for Methamphetamine Addiction
Verified date | November 2023 |
Source | Shanghai Mental Health Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A growing body of evidence suggests a wide range of brain areas including medial prefrontal cortex (mPFC), dorsolateral prefrontal cortex (DLPFC) and other subcortical regions, such as anterior cingulate cortex (ACC) are critical for regulating cognitive control over decisions and involving in drug related cue processing. Previous studies have demonstrated that transcranial magnetic stimulation (rTMS) over dorsolateral prefrontal cortex reduces craving for meth dependences. Specifically, the H7 coil induces a magnetic field can target mPFC and ACC. In this study, the investigators investigated whether repeated dTMS intervention of medial prefrontal and cingulate cortices in methamphetamine addiction could reduce the subjective craving and improve the cognitive abilities.
Status | Completed |
Enrollment | 23 |
Est. completion date | October 30, 2023 |
Est. primary completion date | May 30, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility | Inclusion Criteria: - Methamphetamine dependents - middle school degree or above Exclusion Criteria: - Have contraindications to rTMS (head trauma, epilepsy or history of epilepsy, metal implant etc.) - psychiatric illnesses - intellectual impairment (IQ<90) |
Country | Name | City | State |
---|---|---|---|
China | Nanjing Dalianshan Addiction Rehab Center | Nanjing |
Lead Sponsor | Collaborator |
---|---|
Shanghai Mental Health Center |
China,
Carmi L, Tendler A, Bystritsky A, Hollander E, Blumberger DM, Daskalakis J, Ward H, Lapidus K, Goodman W, Casuto L, Feifel D, Barnea-Ygael N, Roth Y, Zangen A, Zohar J. Efficacy and Safety of Deep Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder: A Prospective Multicenter Randomized Double-Blind Placebo-Controlled Trial. Am J Psychiatry. 2019 Nov 1;176(11):931-938. doi: 10.1176/appi.ajp.2019.18101180. Epub 2019 May 21. — View Citation
Dunlop K, Hanlon CA, Downar J. Noninvasive brain stimulation treatments for addiction and major depression. Ann N Y Acad Sci. 2017 Apr;1394(1):31-54. doi: 10.1111/nyas.12985. Epub 2016 Feb 5. — View Citation
Liu Q, Shen Y, Cao X, Li Y, Chen Y, Yang W, Yuan TF. Either at left or right, both high and low frequency rTMS of dorsolateral prefrontal cortex decreases cue induced craving for methamphetamine. Am J Addict. 2017 Dec;26(8):776-779. doi: 10.1111/ajad.12638. Epub 2017 Nov 14. — View Citation
Liu T, Li Y, Shen Y, Liu X, Yuan TF. Gender does not matter: Add-on repetitive transcranial magnetic stimulation treatment for female methamphetamine dependents. Prog Neuropsychopharmacol Biol Psychiatry. 2019 Jun 8;92:70-75. doi: 10.1016/j.pnpbp.2018.12.018. Epub 2018 Dec 31. — View Citation
Shen Y, Cao X, Tan T, Shan C, Wang Y, Pan J, He H, Yuan TF. 10-Hz Repetitive Transcranial Magnetic Stimulation of the Left Dorsolateral Prefrontal Cortex Reduces Heroin Cue Craving in Long-Term Addicts. Biol Psychiatry. 2016 Aug 1;80(3):e13-4. doi: 10.1016/j.biopsych.2016.02.006. Epub 2016 Feb 12. No abstract available. — View Citation
Su H, Zhong N, Gan H, Wang J, Han H, Chen T, Li X, Ruan X, Zhu Y, Jiang H, Zhao M. High frequency repetitive transcranial magnetic stimulation of the left dorsolateral prefrontal cortex for methamphetamine use disorders: A randomised clinical trial. Drug Alcohol Depend. 2017 Jun 1;175:84-91. doi: 10.1016/j.drugalcdep.2017.01.037. Epub 2017 Mar 29. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | side effect measurements | Side effect scale, including headache, pricking, sleeplessness etc. | every day after each intervention time for the 3 weeks intervention time period | |
Primary | Changes of Cue-induced craving and ERP | Subjective craving (cue induced, 0-100 based VAS, craving scale) and drug cue-ERP (P300 etc. measured) | the day before intervention, 3 weeks after intervention, 1 month after intervention, up to 3 months after intervention | |
Secondary | Changes of cognition: behavioral inhibition | using cognitive tasks: stop-signal task | the day before intervention, 3 weeks after intervention, 1 month after intervention, up to 3 months after intervention | |
Secondary | Changes of cognition: working memory | using cognitive tasks: n-back task | the day before intervention, 3 weeks after intervention, 1 month after intervention, up to 3 months after intervention | |
Secondary | Changes of depression status | depression (Beck Depression inventory scale), high score means worse depression | the day before intervention, 3 weeks after intervention, 1 month after intervention, up to 3 months after intervention | |
Secondary | Changes of anxiety status | Anxiety (Beck anxiety inventory scale), higher score means worse anxiety | the day before intervention, 3 weeks after intervention, 1 month after intervention, up to 3 months after intervention | |
Secondary | Changes of sleep status | sleep status measurements (Pittsburgh Sleep Quality Index scale), higher score means worse sleep | the day before intervention, 3 weeks after intervention, 1 month after intervention, up to 3 months after intervention | |
Secondary | Changes of impulsivity | Impulsivity scale (The Barratt Impulsiveness Scale), higher score means higher impulsivity | the day before intervention, 3 weeks after intervention, 1 month after intervention, up to 3 months after intervention | |
Secondary | Changes of resting EEG network | resting EEG signal (Alpha, Beta, Theta, etc) measurement with 128 Channel EGI system | the day before intervention, 3 weeks after intervention, 1 month after intervention, up to 3 months after intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Recruiting |
NCT04927143 -
Encouraging Abstinence Behavior in a Drug Epidemic
|
Phase 2 | |
Completed |
NCT04449055 -
Pilot TMS for Methamphetamine Use Disorder
|
N/A | |
Completed |
NCT06288997 -
tACS Intervention for Methamphetamine Addiction
|
N/A | |
Active, not recruiting |
NCT05162391 -
Inflammation in Methamphetamine and STIs (IMSTI)
|
N/A | |
Completed |
NCT03336866 -
Study of Antibody for Methamphetamine Outpatient Therapy
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06233799 -
Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder
|
Phase 3 | |
Not yet recruiting |
NCT03748875 -
The Effect of Mindfulness-based Relapse Prevention on Impulsive Control Circuit Among Methamphetamine Dependents
|
N/A | |
Recruiting |
NCT03341078 -
Pilot Study of the Effect of Ibudilast on Neuroinflammation in Methamphetamine Users
|
Phase 2 | |
Active, not recruiting |
NCT03910608 -
Paired Associative Stimulation in Methamphetamine Addiction
|
N/A | |
Terminated |
NCT05283304 -
Monthly Injectable BUP for MA Use Disorder (MURB) Trial
|
Phase 2 | |
Completed |
NCT04563962 -
Contingency Management for PrEP Adherence and/or Methamphetamine Use
|
N/A | |
Not yet recruiting |
NCT05334914 -
ACT for Methamphetamine Use Disorder in Women and Gender Non-Conforming Individuals
|
N/A | |
Terminated |
NCT05034874 -
Multiple-Dose Study to Evaluate the Safety and Efficacy of IXT-m200
|
Phase 2 | |
Recruiting |
NCT06434818 -
Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders
|
Phase 2 | |
Recruiting |
NCT06027814 -
MHealth Incentivized Adherence Plus Patient Navigation
|
N/A | |
Completed |
NCT04544124 -
Delivering Contingency Management in Outpatient Addiction Treatment
|
N/A | |
Completed |
NCT01217970 -
Safety Interaction Trial Ibudilast and Methamphetamine
|
Phase 1 | |
Completed |
NCT03825536 -
Effect of Methamphetamine on Residual Latent HIV Disease Study
|
Phase 4 | |
Recruiting |
NCT03470480 -
rTMS for Craving in Methamphetamine Use Disorder
|
N/A |